Compare Palo Alto Networks Inc (PANW) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs Pfizer Inc — how do they compare? Palo Alto Networks Inc trades at $403.96 (market cap $331.76B), while Pfizer Inc trades at $28.1 (market cap $158.56B). The key difference: Palo Alto Networks Inc is far larger — about 2.1× Pfizer Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Palo Alto Networks Inc for 82 Days and Pfizer Inc for 158 Days on average.
| PANW | PFE | |
|---|---|---|
Market Cap | $331.76B | $158.56B |
Volume | 3,886,927 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $419.91 | $29.02 |
52-Week Low | $141.67 | $23.67 |
Typical Hold Time | 82 Days | 158 Days |
Enterprise Value | $331.19B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks (PANW) trades at $405.41, down 3.45% today but maintains a bullish technical outlook with strong moving average signals. The company demonstrates robust revenue growth, reaching $9.22B in 2025, though net margins compressed to 2.67%. Recent AI security initiatives, including Unit 42 AI defense service, position PANW for continued growth in the cybersecurity sector.
PANW presents a mixed investment case with strong AI-driven growth potential offset by premium valuations (P/E 1,013.93, P/S 26.99). Analyst consensus remains strongly bullish (72% buy ratings) with a $398.70 price target. Key risks include valuation sensitivity and competitive pressures in the rapidly evolving cybersecurity landscape.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
